Börner A R, Voth E, Wienhard K, Wagner R, Schicha H
Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln.
Nuklearmedizin. 1998;37(7):227-33.
This study evaluates F-18-FDG PET of the thyroid in Graves' disease.
Thirty patients were investigated the day before radioiodine therapy, 15 patients 3-10 days after radioiodine therapy. Twenty patients with cancer of the head or neck and normal thyroid function served as controls.
F-18-FDG uptake was higher in Graves' disease patients than in controls. Negative correlations of F-18-FDG uptake with half-life of radioiodine and absorbed radiation dose due to radioiodine therapy were found along with a positive correlation to autoantibody levels.
Thus F-18-FDG PET is likely to give information on the biological activity of Graves' disease as well as on early radiation effects.
本研究评估格雷夫斯病患者甲状腺的F-18-FDG PET检查。
30例患者在放射性碘治疗前一天接受检查，15例患者在放射性碘治疗后3至10天接受检查。20例头颈部癌症且甲状腺功能正常的患者作为对照。
格雷夫斯病患者的F-18-FDG摄取高于对照组。发现F-18-FDG摄取与放射性碘的半衰期及放射性碘治疗所致的吸收辐射剂量呈负相关，与自身抗体水平呈正相关。
因此，F-18-FDG PET可能提供有关格雷夫斯病生物活性以及早期辐射效应的信息。
